Literature DB >> 36007944

MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas.

S Shrot1,2, A Kerpel3, J Belenky3, M Lurye4, C Hoffmann3,2, M Yalon4,2.   

Abstract

BACKGROUND AND
PURPOSE: BRAF and type 1 neurofibromatosis status are distinctive features in pediatric low-grade gliomas with prognostic and therapeutic implications. We hypothesized that DWI metrics obtained through volumetric ADC histogram analyses of pediatric low-grade gliomas at baseline would enable early detection of BRAF and type 1 neurofibromatosis status.
MATERIALS AND METHODS: We retrospectively evaluated 40 pediatric patients with histologically proved pilocytic astrocytoma (n = 33), ganglioglioma (n = 4), pleomorphic xanthoastrocytoma (n = 2), and diffuse astrocytoma grade 2 (n = 1). Apart from 1 patient with type 1 neurofibromatosis who had a biopsy, 11 patients with type 1 neurofibromatosis underwent conventional MR imaging to diagnose a low-grade tumor without a biopsy. BRAF molecular analysis was performed for patients without type 1 neurofibromatosis. Eleven patients presented with BRAF V600E-mutant, 20 had BRAF-KIAA rearrangement, and 8 had BRAF wild-type tumors. Imaging studies were reviewed for location, margins, hemorrhage or calcifications, cystic components, and contrast enhancement. Histogram analysis of tumoral diffusivity was performed.
RESULTS: Diffusion histogram metrics (mean, median, and 10th and 90th percentiles) but not kurtosis or skewness were different among pediatric low-grade glioma subgroups (P < .05). Diffusivity was lowest in BRAF V600E-mutant tumors (the 10th percentile reached an area under the curve of 0.9 on receiver operating characteristic analysis). There were significant differences between evaluated pediatric low-grade glioma margins and cystic components (P = .03 and P = .001, respectively). Well-defined margins were characteristic of BRAF-KIAA or wild-type BRAF rather than BRAF V600E-mutant or type 1 neurofibromatosis tumors. None of the type 1 neurofibromatosis tumors showed a cystic component.
CONCLUSIONS: Imaging features of pediatric low-grade gliomas, including quantitative diffusion metrics, may assist in predicting BRAF and type 1 neurofibromatosis status, suggesting a radiologic-genetic correlation, and might enable early genetic signature characterization.
© 2022 by American Journal of Neuroradiology.

Entities:  

Year:  2022        PMID: 36007944      PMCID: PMC9451619          DOI: 10.3174/ajnr.A7614

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  37 in total

1.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Authors:  Matthew Mistry; Nataliya Zhukova; Daniele Merico; Patricia Rakopoulos; Rahul Krishnatry; Mary Shago; James Stavropoulos; Noa Alon; Jason D Pole; Peter N Ray; Vilma Navickiene; Joshua Mangerel; Marc Remke; Pawel Buczkowicz; Vijay Ramaswamy; Ana Guerreiro Stucklin; Martin Li; Edwin J Young; Cindy Zhang; Pedro Castelo-Branco; Doua Bakry; Suzanne Laughlin; Adam Shlien; Jennifer Chan; Keith L Ligon; James T Rutka; Peter B Dirks; Michael D Taylor; Mark Greenberg; David Malkin; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Uri Tabori
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.

Authors:  Carrie R McDonald; Rachel L Delfanti; Anitha P Krishnan; Kelly M Leyden; Jona A Hattangadi-Gluth; Tyler M Seibert; Roshan Karunamuni; Pia Elbe; Joshua M Kuperman; Hauke Bartsch; David E Piccioni; Nathan S White; Anders M Dale; Nikdokht Farid
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

3.  Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.

Authors:  C-C Wu; R Jain; A Radmanesh; L M Poisson; W-Y Guo; D Zagzag; M Snuderl; D G Placantonakis; J Golfinos; A S Chi
Journal:  AJNR Am J Neuroradiol       Date:  2018-09-06       Impact factor: 3.825

4.  Interimager variability in ADC measurement of the human brain.

Authors:  Naoko Tsujita; Naoki Kai; Yujiro Fujita; Yasuhiro Hiai; Toshinori Hirai; Mika Kitajima; Yasuyuki Yamashita; Ryuji Murakami
Journal:  Magn Reson Med Sci       Date:  2014-04-28       Impact factor: 2.471

5.  BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis.

Authors:  Huy Gia Vuong; Ahmed M A Altibi; Uyen N P Duong; Hanh T T Ngo; Thong Quang Pham; Kar-Ming Fung; Lewis Hassell
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

Review 6.  Pediatric Brain Tumor Genetics: What Radiologists Need to Know.

Authors:  Jehan AlRayahi; Michal Zapotocky; Vijay Ramaswamy; Prasad Hanagandi; Helen Branson; Walid Mubarak; Charles Raybaud; Suzanne Laughlin
Journal:  Radiographics       Date:  2018 Nov-Dec       Impact factor: 5.333

7.  Relative ADC and Location Differ between Posterior Fossa Pilocytic Astrocytomas with and without Gangliocytic Differentiation.

Authors:  J H Harreld; S N Hwang; I Qaddoumi; R G Tatevossian; X Li; J Dalton; K Haupfear; Y Li; D W Ellison
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-28       Impact factor: 3.825

8.  Comparison of 3.0-and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer.

Authors:  Aoi Matsuoka; Masako Minato; Masafumi Harada; Hitoshi Kubo; Yoshikatsu Bandou; Akira Tangoku; Kiichirou Nakano; Hiromu Nishitani
Journal:  Radiat Med       Date:  2008-01-31

9.  Robust Radiomics feature quantification using semiautomatic volumetric segmentation.

Authors:  Chintan Parmar; Emmanuel Rios Velazquez; Ralph Leijenaar; Mohammed Jermoumi; Sara Carvalho; Raymond H Mak; Sushmita Mitra; B Uma Shankar; Ron Kikinis; Benjamin Haibe-Kains; Philippe Lambin; Hugo J W L Aerts
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 10.  Pediatric low-grade glioma in the era of molecular diagnostics.

Authors:  Scott Ryall; Uri Tabori; Cynthia Hawkins
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.